DBV Technologies, a French biotechnology firm specializing in food allergy treatments, has recently revealed that it will face a cash shortfall that could hinder its operations for the next twelve months. This stark warning was disclosed in the company’s third-quarter earnings report, where DBV attributed its depleted cash reserves to persistent operating losses and negative...
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here